Toni M Rudisill1, Motao Zhu2, George A Kelley3, Courtney Pilkerton4, Brandon R Rudisill5. 1. Department of Epidemiology, West Virginia University, PO BOX 9151, Morgantown, WV, 26506, USA; Injury Control Research Center, West Virginia University, PO BOX 9151, Morgantown, WV, 26506, USA. Electronic address: trudisill@hsc.wvu.edu. 2. Department of Epidemiology, West Virginia University, PO BOX 9151, Morgantown, WV, 26506, USA; Center for Injury Research and Policy, The Research Institute at Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH, 43205, USA; Injury Control Research Center, West Virginia University, PO BOX 9151, Morgantown, WV, 26506, USA. Electronic address: Motao.Zhu@NationwideChildrens.org. 3. Department of Biostatistics, West Virginia University, PO BOX 9151, Morgantown, WV, 26506, USA. Electronic address: gkelley@hsc.wvu.edu. 4. Department of Epidemiology, West Virginia University, PO BOX 9151, Morgantown, WV, 26506, USA. Electronic address: cpilkerton@hsc.wvu.edu. 5. 103 Sun Valley, Morgantown, WV, 26508, USA. Electronic address: brandonrudisill@gmail.com.
Abstract
OBJECTIVES: Driving under the influence of prescription and over-the-counter medication is a growing public health concern. A systematic review of the literature was performed to investigate which specific medications were associated with increased risk of motor vehicle collision (MVC). METHODS: The a priori inclusion criteria were: (1) studies published from English-language sources on or after January 1, 1960, (2) licensed drivers 15 years of age and older, (3) peer-reviewed publications, master's theses, doctoral dissertations, and conference papers, (4) studies limited to randomized control trials, cohort studies, case-control studies, or case-control type studies (5) outcome measure reported for at least one specific medication, (6) outcome measure reported as the odds or risk of a motor vehicle collision. Fourteen databases were examined along with hand-searching. Independent, dual selection of studies and data abstraction was performed. RESULTS: Fifty-three medications were investigated by 27 studies included in the review. Fifteen (28.3%) were associated with an increased risk of MVC. These included Buprenorphine, Codeine, Dihydrocodeine, Methadone, Tramadol, Levocitirizine, Diazepam, Flunitrazepam, Flurazepam, Lorazepam, Temazepam, Triazolam, Carisoprodol, Zolpidem, and Zopiclone. CONCLUSIONS: Several medications were associated with an increased risk of MVC and decreased driving ability. The associations between specific medication use and the increased risk of MVC and/or affected driving ability are complex. Future research opportunities are plentiful and worthy of such investigation.
OBJECTIVES: Driving under the influence of prescription and over-the-counter medication is a growing public health concern. A systematic review of the literature was performed to investigate which specific medications were associated with increased risk of motor vehicle collision (MVC). METHODS: The a priori inclusion criteria were: (1) studies published from English-language sources on or after January 1, 1960, (2) licensed drivers 15 years of age and older, (3) peer-reviewed publications, master's theses, doctoral dissertations, and conference papers, (4) studies limited to randomized control trials, cohort studies, case-control studies, or case-control type studies (5) outcome measure reported for at least one specific medication, (6) outcome measure reported as the odds or risk of a motor vehicle collision. Fourteen databases were examined along with hand-searching. Independent, dual selection of studies and data abstraction was performed. RESULTS: Fifty-three medications were investigated by 27 studies included in the review. Fifteen (28.3%) were associated with an increased risk of MVC. These included Buprenorphine, Codeine, Dihydrocodeine, Methadone, Tramadol, Levocitirizine, Diazepam, Flunitrazepam, Flurazepam, Lorazepam, Temazepam, Triazolam, Carisoprodol, Zolpidem, and Zopiclone. CONCLUSIONS: Several medications were associated with an increased risk of MVC and decreased driving ability. The associations between specific medication use and the increased risk of MVC and/or affected driving ability are complex. Future research opportunities are plentiful and worthy of such investigation.
Authors: Jack E Gibson; Richard B Hubbard; Christopher J P Smith; Laila J Tata; John R Britton; Andrew W Fogarty Journal: Am J Epidemiol Date: 2009-01-30 Impact factor: 4.897
Authors: Philippe Corsenac; Emmanuel Lagarde; Blandine Gadegbeku; Bernard Delorme; Aurore Tricotel; Anne Castot; Nicholas Moore; Pierre Philip; Bernard Laumon; Ludivine Orriols Journal: Drug Alcohol Depend Date: 2011-11-21 Impact factor: 4.492
Authors: Ian R H Rockett; Michael D Regier; Nestor D Kapusta; Jeffrey H Coben; Ted R Miller; Randy L Hanzlick; Knox H Todd; Richard W Sattin; Leslie W Kennedy; John Kleinig; Gordon S Smith Journal: Am J Public Health Date: 2012-09-20 Impact factor: 9.308
Authors: Joris C Verster; Edmund R Volkerts; Antonia H C M L Schreuder; Erik J E Eijken; Janet H G van Heuckelum; Dieuwke S Veldhuijzen; Marinus N Verbaten; Isabelle Paty; Mona Darwish; Philippe Danjou; Alain Patat Journal: J Clin Psychopharmacol Date: 2002-12 Impact factor: 3.153
Authors: Marian E Betz; Hailey Hyde; Carolyn DiGuiseppi; Timothy F Platts-Mills; Jason Hoppe; David Strogatz; Howard F Andrews; Thelma J Mielenz; Linda L Hill; Vanya Jones; Lisa J Molnar; David W Eby; Guohua Li Journal: J Am Board Fam Med Date: 2020 Jul-Aug Impact factor: 2.395
Authors: Aaron D Dora-Laskey; Jason E Goldstick; Brooke J Arterberry; Suni Jo Roberts; Rebecca L Haffajee; Amy S B Bohnert; Rebecca M Cunningham; Patrick M Carter Journal: West J Emerg Med Date: 2020-06-19